TFBS Bioscience, Inc.

As of June 30, 2026, TFBS Bioscience, Inc. carries a market capitalization of 707.98M, placing it among publicly traded companies globally. Its enterprise value stands at 523.11M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, TFBS Bioscience, Inc. has 35.40M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, TFBS Bioscience, Inc. maintains a current ratio of 2.40, meaning it holds 2.4x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2026.

As of the close on October 22, 2026, TFBS Bioscience, Inc.'s stock has declined approximately 21.50% over the past 52 weeks. The 50-day moving average sits at 19.47, while the 200-day moving average is 20.34.

As of June 30, 2026, TFBS Bioscience, Inc. holds 394.62M in cash and equivalents against 209.74M in total debt, resulting in a net debt position of -168.22M. Total book value stands at 1.13B, with working capital of 293.49M providing operational flexibility.

TFBS Bioscience, Inc.'s most recent stock split took place on September 27, 2023 with a 25:26 split ratio.